TN2014000375A1 - 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors - Google Patents
2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitorsInfo
- Publication number
- TN2014000375A1 TN2014000375A1 TNP2014000375A TN2014000375A TN2014000375A1 TN 2014000375 A1 TN2014000375 A1 TN 2014000375A1 TN P2014000375 A TNP2014000375 A TN P2014000375A TN 2014000375 A TN2014000375 A TN 2014000375A TN 2014000375 A1 TN2014000375 A1 TN 2014000375A1
- Authority
- TN
- Tunisia
- Prior art keywords
- amino
- kinase inhibitors
- phenyl substituted
- pyrimidine derivatives
- raf kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 | |
| PCT/US2013/029084 WO2013134243A1 (fr) | 2012-03-07 | 2013-03-05 | Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000375A1 true TN2014000375A1 (en) | 2015-12-21 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2014000375A TN2014000375A1 (en) | 2012-03-07 | 2014-09-03 | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8741911B2 (fr) |
| EP (1) | EP2850082B1 (fr) |
| JP (1) | JP2015509536A (fr) |
| KR (1) | KR20140129087A (fr) |
| CN (1) | CN104302646B (fr) |
| AP (1) | AP2014007899A0 (fr) |
| AR (1) | AR090151A1 (fr) |
| AU (1) | AU2013230146B2 (fr) |
| BR (1) | BR112014018528A8 (fr) |
| CA (1) | CA2863673A1 (fr) |
| CL (1) | CL2014002220A1 (fr) |
| CO (1) | CO7010837A2 (fr) |
| CR (1) | CR20140378A (fr) |
| CY (1) | CY1117846T1 (fr) |
| DK (1) | DK2850082T3 (fr) |
| DO (1) | DOP2014000200A (fr) |
| EA (1) | EA024824B1 (fr) |
| EC (1) | ECSP14017584A (fr) |
| ES (1) | ES2584387T3 (fr) |
| HK (1) | HK1202541A1 (fr) |
| HR (1) | HRP20160654T1 (fr) |
| HU (1) | HUE028095T2 (fr) |
| IL (1) | IL234052A (fr) |
| IN (1) | IN2014MN01575A (fr) |
| LT (1) | LT2850082T (fr) |
| MA (1) | MA37316B1 (fr) |
| ME (1) | ME02423B (fr) |
| MX (1) | MX2014010701A (fr) |
| NZ (1) | NZ627454A (fr) |
| PE (1) | PE20142338A1 (fr) |
| PH (1) | PH12014501986B1 (fr) |
| PT (1) | PT2850082T (fr) |
| RS (1) | RS54840B1 (fr) |
| SG (1) | SG11201404969YA (fr) |
| SI (1) | SI2850082T1 (fr) |
| TN (1) | TN2014000375A1 (fr) |
| TW (1) | TW201348233A (fr) |
| UA (1) | UA112340C2 (fr) |
| WO (2) | WO2013134252A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| KR20190017767A (ko) * | 2016-06-10 | 2019-02-20 | 노파르티스 아게 | C-raf 억제제의 치료적 용도 |
| US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
| WO2018200981A1 (fr) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Composés conjugués de dégradation de raf |
| CA3085835A1 (fr) | 2017-12-21 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Nouvelles pyridopyrimidinones a substitution benzylamino et derives a utiliser en tant qu'inhibiteurs de sos1 |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| CA3089630A1 (fr) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Polytherapie pour le traitement de la mastocytose |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP4303583A3 (fr) | 2018-12-28 | 2024-03-27 | Deciphera Pharmaceuticals, LLC | Procédés de traitement de troubles à l'aide d'inhibiteurs de csf1r |
| LT3921030T (lt) | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai |
| EP3962484A4 (fr) * | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | Inhibiteurs de kinases raf |
| JP2022531932A (ja) | 2019-05-10 | 2022-07-12 | デシフェラ・ファーマシューティカルズ，エルエルシー | ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| EP3966207B1 (fr) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation |
| MX2021015628A (es) | 2019-06-17 | 2022-04-18 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412A1 (fr) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
| EP4084778B1 (fr) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Formulations d'inhibiteur de kinase amorphe et leurs procédés d'utilisation |
| EP4084779B1 (fr) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree |
| AU2021285032A1 (en) | 2020-06-02 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2022060996A1 (fr) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibiteurs de raf kinases |
| WO2022081469A1 (fr) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibiteurs de kinases raf |
| CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| JP2024516972A (ja) | 2021-04-23 | 2024-04-18 | キネート バイオファーマ インク． | Ｒａｆ阻害薬による癌の処置 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| EP4441056A1 (fr) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer |
| EP4441050A1 (fr) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer |
| EP4441053A1 (fr) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer |
| IL312905A (en) | 2021-12-01 | 2024-07-01 | Boehringer Ingelheim Int | 2-amino-3-cyano ring thiophenes and history for cancer therapy |
| CN118574836A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物 |
| EP4441051A1 (fr) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés |
| EP4444430A1 (fr) | 2021-12-09 | 2024-10-16 | Deciphera Pharmaceuticals, LLC | Inhibiteurs de kinase raf et leurs procédés d'utilisation |
| WO2023118250A1 (fr) | 2021-12-23 | 2023-06-29 | Boehringer Ingelheim International Gmbh | 8-aza-quinazolines utilisés en tant qu'inhibiteurs de sos1 pénétrant dans le cerveau |
| WO2023173017A1 (fr) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Inhibiteurs de kras pour le traitement d'une maladie |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US20240174641A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| US20240174642A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024088991A1 (fr) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques capables d'activer le sting |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447405A4 (fr) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| TW201139436A (en) * | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/fr active Active
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/fr active Application Filing
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/fr active Application Filing
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko active IP Right Grant
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/fr unknown
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-03-05 CA CA2863673A patent/CA2863673A1/fr not_active Abandoned
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986B1/en unknown
-
2015
- 2015-03-26 HK HK15103082.6A patent/HK1202541A1/xx unknown
-
2016
- 2016-06-10 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501986A1 (en) | 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| EP3268000A4 (fr) | Dérivés de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de cdk | |
| IL265918B (en) | Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| ZA201802181B (en) | 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | |
| IL228968A0 (en) | Kinase-inhibiting pyrazolo[4,3-d]pyrimidine compounds, preparations containing them and their uses | |
| IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| MX2014015271A (es) | Inhibidor de jak1 y jak2. |